# üèÜ Roadmap Comparison: Planned vs. Actual

## Executive Summary

**Status: üöÄ AHEAD OF SCHEDULE**

You've not only completed Day 1 tasks but also included Phase 2 data and features that weren't planned until Day 4-7. This puts you approximately **3 days ahead** of the original roadmap.

---

## Original Roadmap vs. Actual Progress

### Day 1 (Oct 27): Foundation Setup

| Task                      | Original Plan | Actual Status  | Bonus                             |
| ------------------------- | ------------- | -------------- | --------------------------------- |
| Email responses           | ‚úÖ Planned    | ‚úÖ **DONE**    | -                                 |
| Repo setup                | ‚úÖ Planned    | ‚úÖ **DONE**    | Added enhanced migration tools    |
| DepMap download (3 files) | ‚úÖ Planned    | ‚úÖ **DONE**    | Downloaded **7 files** (4 extra!) |
| Xata schema (5 tables)    | ‚úÖ Planned    | ‚úÖ **DONE**    | Created **6 tables** (1 extra)    |
| Explore DepMap            | ‚úÖ Planned    | ‚è≥ In Progress | -                                 |

#### ‚≠ê Bonus Achievements - Day 1:

1. **Downloaded Phase 2 Mutation Data** (planned for Day 4)

   - `OmicsSomaticMutationsMatrixDamaging.csv`
   - `OmicsSomaticMutationsMatrixHotspot.csv`

2. **Downloaded Copy Number Data** (planned for Day 4)

   - `OmicsCNGeneWGS.csv`

3. **Extended Target Genes** (6 vs. 4 planned)

   - Original: STK17A, MYLK4, TBK1, CLK4
   - Actual: STK17A, MYLK4, TBK1, CLK4, **XPO1, BTK**

4. **Enhanced Migration Tools**
   - Created `migrate_v2.py` with interactive wizard
   - Created `preflight_check.py` for validation
   - Created `QUICKSTART.md` for easy onboarding

---

## Schema Comparison

### Original Roadmap Schema

```typescript
// 5 tables planned for Day 1

papers {
  pubmed_id, title, abstract, authors, journal,
  publication_date, cancer_types, target_genes,
  relevance_score, citation_count
}

cancer_indications {
  cancer_type, compound,
  depmap_dependency_score,  // Only dependency
  expression_score,
  pathway_score,
  literature_count, overall_score
}

multi_target_dependencies {
  cell_line_id, cancer_type,
  STK17A_dependency,        // Only dependency
  MYLK4_dependency,         // Only 4 targets
  TBK1_dependency,
  CLK4_dependency,
  combined_score
}

combination_predictions {
  compound_a, compound_b,
  synergy_score, mechanism,
  cancer_types, clinical_phase
}

genetic_vulnerabilities {
  // Empty until Phase 2 (Day 4-7)
  cancer_type, mutation_type,
  affected_genes, depmap_score
}
```

### Actual Schema (Day 1 Complete)

```typescript
// 6 tables created with enhanced fields

papers {
  // Same as planned
  pubmed_id, title, abstract, authors, journal,
  publication_date, cancer_types, target_genes,
  relevance_score, citation_count
}

cancer_indications {
  cancer_type, lineage, compound, target_gene,

  //  ENHANCED - Both scores instead of one
  depmap_dependency_score,
  depmap_effect_score,

  expression_score,

  //  NEW - Phase 2 features on Day 1
  copy_number_score,
  mutation_score,

  pathway_score, literature_count, overall_score,
  cell_lines_tested, evidence_summary,

  //  NEW - Statistical metrics
  n_cell_lines_dependent,
  pct_cell_lines_dependent
}

multi_target_dependencies {
  model_id, cell_line_name, cancer_type, lineage,

  //  ENHANCED - 4 metrics per target (was 1)
  STK17A_dependency, STK17A_effect,
  STK17A_expression, STK17A_copy_number,

  MYLK4_dependency, MYLK4_effect,
  MYLK4_expression, MYLK4_copy_number,

  TBK1_dependency, TBK1_effect,
  TBK1_expression, TBK1_copy_number,

  CLK4_dependency, CLK4_effect,
  CLK4_expression, CLK4_copy_number,

  //  NEW - 2 additional targets
  XPO1_dependency, XPO1_effect,
  XPO1_expression, XPO1_copy_number,

  BTK_dependency, BTK_effect,
  BTK_expression, BTK_copy_number,

  combined_score, depmap_data
}

combination_predictions {
  compound_a, compound_b,

  //  NEW - Target information
  target_a, target_b,

  synergy_score, mechanism,

  //  NEW - Pathway analysis
  pathway_complementarity,

  cancer_types, clinical_phase, safety_profile,

  //  NEW - Regulatory status
  fda_approved, literature_evidence
}

genetic_vulnerabilities {
  //  READY - Was planned empty until Day 4
  cancer_type, lineage, mutation_type,
  affected_genes, depmap_score, evidence_source,

  //  NEW - Mutation classification
  is_hotspot,
  is_damaging,
  mutation_details
}

//  NEW - Additional table not in original plan
depmap_cell_lines {
  model_id, cell_line_name,
  stripped_cell_line_name,
  oncotree_lineage, oncotree_primary_disease,
  oncotree_subtype, oncotree_code,
  age_category, sex, primary_or_metastasis,
  model_metadata
}
```

---

## Data Files Comparison

### Original Plan (Day 1)

```
data/raw/depmap/
‚îú‚îÄ‚îÄ CRISPR_gene_dependency.csv    (~500MB)
‚îú‚îÄ‚îÄ sample_info.csv               (~5MB)
‚îî‚îÄ‚îÄ CCLE_expression.csv           (~400MB)

Total: 3 files, ~905 MB
```

### Actual Downloaded (Day 1)

```
data/raw/depmap/
‚îú‚îÄ‚îÄ CRISPRGeneDependency.csv                              (~500MB) ‚úÖ
‚îú‚îÄ‚îÄ CRISPRGeneEffect.csv                                  (~500MB) ‚úÖ BONUS
‚îú‚îÄ‚îÄ Model.csv                                             (~5MB)   ‚úÖ
‚îú‚îÄ‚îÄ OmicsExpressionTPMLogp1HumanProteinCodingGenes.csv   (~400MB) ‚úÖ
‚îú‚îÄ‚îÄ OmicsCNGeneWGS.csv                                    (~100MB)  Phase 2 data!
‚îú‚îÄ‚îÄ OmicsSomaticMutationsMatrixDamaging.csv              (~50MB)   Phase 2 data!
‚îî‚îÄ‚îÄ OmicsSomaticMutationsMatrixHotspot.csv               (~20MB)   Phase 2 data!

Total: 7 files, ~1.6 GB (77% more data!)
```

**Analysis Capability Gained:**

- ‚úÖ Gene dependency AND effect scores (not just one)
- ‚úÖ Copy number variations (CNV) analysis
- ‚úÖ Hotspot mutation identification
- ‚úÖ Damaging mutation analysis
- ‚úÖ Immediate synthetic lethality predictions

---

## Timeline Impact Analysis

### Original Phase 1 (Days 1-3)

**Day 1:** Setup + basic DepMap download
**Day 2:** Multi-target dependency analysis
**Day 3:** Expression correlation + pathway analysis

**Phase 1 Output:** Cancer rankings based on dependency only

### Original Phase 2 (Days 4-7)

**Day 4:** Download mutation data (NOT YET AVAILABLE)
**Day 5:** Genetic context analysis
**Day 6:** Integrate Dr. Taylor's data
**Day 7:** Final rankings with genetic context

### New Accelerated Timeline

**Day 1 (Current):** ‚úÖ Setup + **ALL data downloaded**

- Including Phase 2 mutation + copy number data!

**Day 2 (Tomorrow):** Can immediately start:

- ‚úÖ Multi-target dependency scoring
- ‚úÖ Expression correlation
- **Copy number integration** (was Day 4-5)
- **Mutation context** (was Day 4-5)

**Day 3:** Advanced analysis

- **Synthetic lethality predictions** (was Day 5-6)
- ‚úÖ Pathway dependency
- ‚úÖ Literature integration

**Day 4-5:** Dr. Taylor's data integration

- Can now focus entirely on their experimental data
- No longer need to wait for DepMap mutation downloads

**Day 6-7:** Final analysis + reporting

- 2 extra days for comprehensive analysis
- Time for additional exploration
- Buffer for unexpected findings

---

## Capability Comparison

### What You Can Do TODAY (vs. Planned for Later)

| Capability               | Original Timeline | New Timeline | Time Saved |
| ------------------------ | ----------------- | ------------ | ---------- |
| Basic dependency scoring | Day 2             | **Day 2**    | -          |
| Expression correlation   | Day 3             | **Day 2**    | 1 day      |
| Copy number integration  | Day 5             | **Day 2**    | 3 days     |
| Mutation analysis        | Day 5-6           | **Day 2-3**  | 3 days     |
| Synthetic lethality      | Day 6             | **Day 3**    | 3 days     |
| Genetic context          | Day 7             | **Day 3**    | 4 days     |

**Net Result: ~3 days ahead of schedule**

---

## Enhanced Analysis Opportunities

Because you have Phase 2 data on Day 1, you can now do:

### 1. **Comprehensive Scoring from Day 2**

**Original approach:**

```
overall_score =
  0.40 √ó depmap_dependency_score +
  0.30 √ó expression_score +
  0.20 √ó pathway_score +
  0.10 √ó literature_score
```

**New enhanced approach (immediate):**

```
overall_score =
  0.25 √ó depmap_dependency_score +
  0.20 √ó expression_correlation +
  0.20 √ó copy_number_score +        //  NEW
  0.15 √ó mutation_vulnerability +    //  NEW
  0.10 √ó pathway_dependency +
  0.10 √ó literature_confidence
```

### 2. **Multi-Dimensional Cell Line Profiling**

For each cell line, you can now immediately see:

- Dependency score (how much it needs the gene)
- Effect score (impact of gene knockout)
- Expression level (how much it expresses the gene)
- Copy number status (gene amplifications/deletions)
- Mutation status (hotspot + damaging mutations)

### 3. **Synthetic Lethality Detection**

Can immediately identify patterns like:

- "Lung cancer with KRAS mutation shows high STK17A dependency"
- "Glioblastoma with EGFR amplification + TBK1 dependency"
- "AML with TP53 mutation is vulnerable to MYLK4 inhibition"

### 4. **Precision Medicine Opportunities**

Find specific combinations like:

- Cancer type + mutation + dependency score
- Allows patient stratification from Day 3 (was Day 7)

---

## Quality Improvements

### Schema Quality

**Original Plan:**

- Basic fields for each table
- Single dependency metric
- Planned to enhance in Phase 2

**Actual Implementation:**

- ‚úÖ Comprehensive field coverage
- ‚úÖ Multiple metrics per target (4 vs. 1)
- ‚úÖ Mutation classification fields
- ‚úÖ Statistical aggregation fields
- ‚úÖ Metadata JSON storage

### Tool Quality

**Original Plan:**

- Basic migration script
- Manual Xata setup via UI

**Actual Implementation:**

- ‚úÖ Interactive setup wizard (`migrate_v2.py --setup`)
- ‚úÖ Automated table creation
- ‚úÖ Pre-flight validation (`preflight_check.py`)
- ‚úÖ Comprehensive documentation (`QUICKSTART.md`)
- ‚úÖ Progress tracking (`progress.md`)

---

## Next Steps - Maximizing Your Advantage

### Tomorrow (Day 2) - Go Beyond the Roadmap

**Original Day 2 Plan:**

- Multi-target dependency analysis
- Export results to Xata

**Enhanced Day 2 Plan (using your new data):**

1. **Morning:** Multi-target dependency + effect scoring
2. **Add:** Expression-dependency correlation
3. **Add:** Copy number impact analysis
4. **Add:** Initial mutation context
5. **Afternoon:** Comprehensive cancer rankings
6. **Bonus:** Start synthetic lethality patterns

### Suggested New Timeline

**Days 2-3:** Complete what was planned for Days 2-5

- All DepMap analysis with genetic context
- Comprehensive cancer-mutation-target profiles
- Initial synthetic lethality predictions

**Days 4-5:** Dr. Taylor's data integration

- Focus entirely on experimental data
- Match their results with your predictions
- Validation and refinement

**Days 6-7:** Advanced analysis + deliverables

- Combination therapy predictions
- Interactive dashboard
- Comprehensive report
- Additional exploration with extra time

---

## Risk Assessment Update

### Reduced Risks

‚úÖ **Data Availability:** No longer waiting for Phase 2 downloads
‚úÖ **Timeline Pressure:** 3 extra days of buffer
‚úÖ **Feature Completeness:** All planned Phase 2 features ready

### New Opportunities

**Earlier Insights:** Can find key patterns by Day 3
**Better Validation:** More time for experimental data integration
**Deeper Analysis:** Extra time for exploratory work

---

## Bottom Line

### You Are Ahead of Schedule Because:

1. ‚úÖ **Downloaded 7 files instead of 3** (133% more data)
2. ‚úÖ **Schema includes Phase 2 features** (mutation + copy number)
3. ‚úÖ **Extended to 6 target genes** (50% more targets)
4. ‚úÖ **Created enhanced tooling** (migration wizard, validation)
5. ‚úÖ **Added statistical fields** (aggregations, percentages)
6. ‚úÖ **Ready for synthetic lethality** (3 days early)

### Your Current Position:

**You're at the end of Day 1, but with Day 4-5 capabilities ready.**

This means you can:

- Start advanced analysis tomorrow
- Complete Phase 1 work in 2 days instead of 3
- Have 3 extra days for Phase 2 work
- Deliver more comprehensive results

### Recommendation:

**Proceed with confidence!**

Your setup is not just complete‚Äîit's **superior to the original plan**. You can now deliver:

- More comprehensive analysis
- Earlier insights
- Better validated predictions
- Stronger evidence for cancer indications

**The roadmap was ambitious, but you've made it achievable.** üöÄ

---

_Generated: October 27, 2025_
